S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

NASDAQ:CFRX - ContraFect Stock Price, Forecast & News

$10.84
+0.21 (+1.98 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$10.24
Now: $10.84
$11.39
50-Day Range
$0.58
MA: $3.33
$11.30
52-Week Range
$2.69
Now: $10.84
$13.40
Volume304,817 shs
Average Volume289,253 shs
Market Capitalization$166.20 million
P/E Ratio27.10
Dividend YieldN/A
Beta0.68
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CFRX
CUSIPN/A
Phone914-207-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.70 per share

Profitability

Net Income$-37,680,000.00

Miscellaneous

Employees20
Market Cap$166.20 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive CFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter.


ContraFect (NASDAQ:CFRX) Frequently Asked Questions

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

When did ContraFect's stock split? How did ContraFect's stock split work?

Shares of ContraFect reverse split before market open on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split.

How were ContraFect's earnings last quarter?

ContraFect Corp (NASDAQ:CFRX) posted its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.77) by $0.07. View ContraFect's Earnings History.

When is ContraFect's next earnings date?

ContraFect is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for ContraFect.

What price target have analysts set for CFRX?

2 equities research analysts have issued 12-month price targets for ContraFect's shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate ContraFect's share price to reach $17.50 in the next twelve months. This suggests a possible upside of 61.4% from the stock's current price. View Analyst Price Targets for ContraFect.

What is the consensus analysts' recommendation for ContraFect?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect.

Has ContraFect been receiving favorable news coverage?

Media coverage about CFRX stock has trended extremely negative this week, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ContraFect earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for ContraFect.

Are investors shorting ContraFect?

ContraFect saw a increase in short interest in January. As of January 15th, there was short interest totalling 615,400 shares, an increase of 80.0% from the December 31st total of 341,900 shares. Based on an average trading volume of 1,380,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 2.2% of the company's stock are short sold. View ContraFect's Current Options Chain.

Who are some of ContraFect's key competitors?

What other stocks do shareholders of ContraFect own?

Who are ContraFect's key executives?

ContraFect's management team includes the folowing people:
  • Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 66)
  • Mr. Michael Messinger CPA, CPA, CFO & Chief Accounting Officer (Age 44)
  • Ms. Nancy Dong, VP of Fin. & Admin. (Age 54)
  • Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 50)
  • Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 57)

Who are ContraFect's major shareholders?

ContraFect's stock is owned by many different of retail and institutional investors. Top institutional investors include Birchview Capital LP (18.44%), Oracle Investment Management Inc. (9.80%), Renaissance Technologies LLC (6.80%), Trellus Management Company LLC (3.91%), AMG National Trust Bank (0.05%) and Sheaff Brock Investment Advisors LLC (0.03%). Company insiders that own ContraFect stock include Cary Sucoff, Fosun Pharmaceutical Shanghai and Michael Messinger. View Institutional Ownership Trends for ContraFect.

Which major investors are selling ContraFect stock?

CFRX stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc.. View Insider Buying and Selling for ContraFect.

Which major investors are buying ContraFect stock?

CFRX stock was bought by a variety of institutional investors in the last quarter, including Birchview Capital LP, Renaissance Technologies LLC, Trellus Management Company LLC, AMG National Trust Bank and Sheaff Brock Investment Advisors LLC. Company insiders that have bought ContraFect stock in the last two years include Cary Sucoff and Michael Messinger. View Insider Buying and Selling for ContraFect.

How do I buy shares of ContraFect?

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $10.84.

How big of a company is ContraFect?

ContraFect has a market capitalization of $166.20 million. The biotechnology company earns $-37,680,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. ContraFect employs 20 workers across the globe.View Additional Information About ContraFect.

What is ContraFect's official website?

The official website for ContraFect is http://www.contrafect.com/.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]


MarketBeat Community Rating for ContraFect (NASDAQ CFRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel